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Abstract 
Background & aims: Gallstone disease is related to hypersecretion of cholesterol in bile, and low 
serum phytosterol levels. We examined how genetic polymorphisms of sterol transporters affect 
childhood cholesterol metabolism trait predicting adult gallstone disease. 
Patients and methods: In retrospective controlled study, we determined D19H polymorphism of 
ABCG8 gene, genetic variation at Niemann-Pick C1-like 1 (NPC1L1) gene locus (rs41279633, 
rs17655652, rs2072183, rs217434 and rs2073548), and serum cholesterol, noncholesterol sterols and 
lipids in children affected by gallstones decades later (n=66) and controls (n=126). 
Results: In childhood, phytosterols were lower (9.7%-23.4%) in carriers of risk allele 19H compared 
to 19D homozygotes. Lowest campesterol/cholesterol tertile consisted of 1.9-times more future 
gallstone subjects, and 3.7-times more 19H carriers than highest one. Campesterol/cholesterol-ratio 
was highest in 19D homozygote controls, but ~11% lower in gallstone 19D homozygotes and ~25% 
lower among gallstone and control carriers of 19H. Gallstone subjects with alleles CC of rs41279633 
and TT of rs217434 of NPC1L1 had ~18% lower campesterol/cholesterol-ratio compared to mutation 
carriers. 
Conclusions: Risk trait of cholesterol metabolism (low phytosterols) in childhood favouring 
cholesterol gallstone disease later in adulthood is influenced by risk variant 19H of ABCG8 and 
obviously also other factors. NPC1L1 variants have minor influence on noncholesterol sterols. 
 
Keywords: Cholesterol; noncholesterol sterols; plant sterols; surrogates of cholesterol absorption 
 
1. Introduction 
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Adult gallstone disease represents a prevalent and costly health problem. The vast majority - over 
90% - of gallstones in adults are cholesterol stones in the Western world [1 - 4]. Although the 
cholesterol gallstone disease has a multifactorial etiology consisting of genetic and environmental 
factors, the adults predisposed to the gallstone disease share as a common feature increased biliary 
output of cholesterol [5-7]. 
Heterodimeric sterol transporter ABCG5/G8 determines biliary secretion of cholesterol and plant 
sterols from the hepatocyte into the biliary canaliculus and their efflux out of the enterocyte into the 
intestinal lumen [8, 9]. Niemann-Pick C1-like 1 (NPC1L1) protein has an essential role in intestinal 
cholesterol up-take into the enterocytes, and, additionally in humans, in the retention of biliary 
cholesterol by the hepatocytes [10]. Consequently, the biliary secretion of cholesterol and plant sterols 
is determined by the balance between their efflux across the hepatocyte canalicular membrane 
governed by these transporters [11]. The adult gallstone disease has been related to ABCG8 gene 
polymorphism D19H (rs11887534) in several studies [5, 12]. However, Krawczyk and co-workers 
suggested that ABCG8 polymorphism did not fully explain the sterol metabolic trait of the gallstone 
carriers [5]. Theoretically, decreased expression or function of the hepatic NPC1L1 transporter (e.g., 
by genetic loss-of-function variants), or its increased expression at the brush border of the enterocytes 
are both likely to increase biliary cholesterol secretion and the propensity for gallstone formation 
[13]. Overall, results concerning the relationship between the cholesterol gallstone disease and 
polymorphism of NPC1L1 have remained controversial [14, 15]. Interestingly, Lauridsen and co-
workers showed in their large population-based study that genetic variation in NPC1L1 that is 
associated with lowered cholesterol absorption is also associated with a reduced risk of ischaemic 
vascular disease, and reduction in serum LDL-cholesterol, but with a concomitant rise in the 
incidence of gallstone disease [15]. 
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Among the serum noncholesterol sterols, cholestanol (a derivative of endogenous cholesterol), and 
phytosterols campesterol and sitosterol reflect positively the absorption efficiency of cholesterol [16-
20]. Opposite to that, the cholesterol precursor sterols, cholestenol, lathosterol, and desmosterol, 
mirror whole-body cholesterol synthesis [16, 18, 20], and also the activity of hepatic hydroxy-methyl-
glutaryl-CoA reductase [21, 22]. Thus, determination of cholestanol, the cholesterol precursor sterols 
and phytosterols in serum provides a signature of cholesterol metabolism, which evaluated together 
with the risk mutations of the genes encoding the major canalicular sterol transporters helps to assess 
the etiopathogenesis of the gallstone disease. Our previous results indicated that cholesterol 
metabolism trait characterized by low serum levels of surrogate markers of cholesterol absorption 
precedes adult gallstone disease already in childhood [7]. Recent data from morbidly obese subjects 
suggest that low serum plant sterols among patients with gallstones indicate potentially inherited 
alterations in intestinal absorption and biliary transport of sterols [23].  
It has remained unexplored (I) how D19H of ABCG8 and polymorphisms at NPC1L1 locus modify 
metabolism of cholesterol in childhood, and (II) to what extent are these genetic polymorphisms 
related to the childhood cholesterol metabolism trait predicting the adult gallstone disease. 
To this end, we performed a retrospective controlled study, in which we evaluated how D19H 
polymorphism of the ABCG8 gene and genetic variation at the NPC1L1 gene locus affect metabolism 
of cholesterol, plant sterols and lipids in a pediatric cohort affected by the gallstone disease decades 
later in adulthood, and compared the results with the age-, gender- and body mass index (BMI) 
matched control subjects. The study subjects were participants of the prospective Cardiovascular Risk 
in Young Finns Study [24-26].  
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2. Subjects and methods 
2.1 Subjects and ethics 
The Cardiovascular Risk in Young Finns Study is a multicenter follow-up study of Finnish children 
and adolescents [24-26]. The first cross-sectional survey was conducted in 1980, when 3596 
participants, ages 3, 6, 9, 12, 15 and 18 years, were randomly chosen from the five geographic study 
areas of Finland through the national population register. At the study inclusion, determination of 
serum lipids, dietary survey and collection of serum samples was performed. In the present study, the 
participants were followed up based on the unique personal identification codes through the Care 
Registers for Social Welfare and Health Care until 2012 for the diagnosis of gallstone disease and 
regular medications. Gallstone disease was defined as a hospital discharge diagnosis that included 
ICD-10 codes K80.0-K80.8 as either a primary or secondary code. In Finland, the hospital discharge 
register includes all hospitals. Both primary and secondary codes were used to ensure capture of all 
gallstone disease patients. For each case, who developed gallstone disease (n=95) two unaffected 
controls (n=190) were matched for BMI, age and sex recorded at the start of the follow-up in 1980. 
For the purposes of the present study, the respective BMI-values in year 1983 were registered. The 
frozen serum samples of the patients and controls obtained at the first survey in 1980 were retrieved 
for measurement of cholesterol and non-cholesterol sterols, and the preliminary results of these data 
without knowledge of the genetic data have been reported earlier [7]. Of these cases and controls, 
genome-wide genotyping data was available in 66 cases and 126 controls. Data of NPC1L1 gene 
variants was missing in one of the gallstone patients. All the analyses were repeated after excluding 
subjects taking lipid-lowering medications at some point during the follow-up (one for the gallstone 
and two for the control cohort) with essentially similar results. 
Consumption of vegetables (excluding potatoes), fruits and juices, meat meals and fish meals had 
been recorded in year 1980 and classified: 1 = once a day or more frequently, 2 = almost every day, 
3 = twice a week, 4 = once a week, 5 = once or twice a month and 6 = seldom or never. 
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All subjects volunteered to the study and provided their written informed consent. The study followed 
up the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the 
human research committee. The Ethics Committee of the Turku University Central Hospital had 
accepted the study protocol. 
 
2.2. Biochemical determinations and DNA analysis 
Standard enzymatic methods were used for determination of serum total cholesterol, HDL cholesterol 
and serum triglyceride concentrations, and that of LDL cholesterol was calculated. Details of the 
methods have been described previously [26]. 
Serum squalene, cholesterol and non-cholesterol sterols were measured by gas-liquid 
chromatography (GLC) using a 50-m Ultra 2 capillary column (Agilent Technologies, Wilmington, 
Del) (for detailed method description see ref. 27). The procedure uses 5-cholestane as internal 
standard, and it measures the serum concentrations of squalene, cholesterol, cholestanol, cholestenol, 
desmosterol, lathosterol, campesterol, sitosterol, stigmasterol and avenasterol, in this order of 
retention time. The serum levels of major lipoproteins, which transport non-cholesterol sterols, 
particularly LDL, vary with age. For this reason, the values were calculated as ratios to cholesterol 
measured in the same GLC run, expressed as 100 x mmol/mol of cholesterol, and given in the text as 
ratios. Serum cholestenol, lathosterol, and desmosterol ratios are called surrogate or relative synthesis 
markers, and the ratios of cholestanol, campesterol, sitosterol and avenasterol are called surrogate or 
relative markers of cholesterol absorption efficiency. Calculation of synthesis marker/absorption 
marker ratios, e.g., lathosterol/sitosterol reflected whole-body cholesterol metabolism [28]. 
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Five single nucleotide polymorphisms (SNPs) in the NPC1L1 locus were genotyped in this study 
because they are related to serum cholesterol levels: -18C>A (rs41279633), -133A>G (rs17655652), 
1679C>G or L272L (rs2072183), 27621T>C or V1296V (rs217434) and g-762T>C (rs2073548). 
Genotyping of all SNPs was performed using Illumina Human 670K BeadChip. Genotypes were 
called using the Illumina clustering algorithm [29] and imputation was performed using SHAPEIT 
v1 [30] and IMPUTE2 [31] software and the 1000G Phase I Integrated Release Version 3 as a 
reference panel [32]. Two of the candidate SNPs analyzed in this study were directly genotyped 
(rs17655652 and rs217434), the other four were imputed. Both genotyped SNPs were in Hardy-
Weinberg equilibrium (p>0.05). Since the values of imputed genotypes account for the uncertainty 
of imputation and are not integer values, the key assumptions of traditional Hardy-Weinberg 
equilibrium test are not met. Instead, we used post-imputation metric “info score” to measure the 
quality of imputation for these SNPs. For all four SNPs, the info score was > 0.9 indicating high 
quality imputations. In addition, the allele frequencies for all six SNPs were very similar to those 
reported for European and Finnish populations by the 1000 Genomes Project [32]. 
 
2.3. Statistical analyses 
The data were analyzed for significance and normality with the Number Crunching Statistical 
Software™ (NCSS™, Statistical Solutions Ltd., 2006, Kaysville, Utah). Most of the variables were 
normally distributed, but logarithmic transformations were performed in skewed distributions. 
Multiple comparisons among subgroups (gallstone subjects and control subjects with or without 
variants) were performed with analysis of variance (ANOVA) applying BMI, age, and consumption 
of vegetables as covariates. If the P value of ANOVA was below 0.05, comparisons between two 
groups (cases versus controls and subjects with versus without gene variants) were performed using 
two-sided unpaired t-test. Dietary data were analyzed with Kruskall-Wallis one-way ANOVA with 
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Bonferroni adjustment and Mann-Whitney U test. Statistical analysis for non-continuous variables 
was performed by using Fisher’s exact test. The amount of subjects needed for the study was 
evaluated according to the results of Gylling and co-workers [33], which revealed that serum 
campesterol/cholesterol ratio is 32.6% lower in the subjects with risk variant 19H than in the subjects 
with 19D. The type I error rate and the power of the study were considered to be 5% and 80%, 
respectively. Consequently, at least 12 subjects in the subgroup with the risk variant 19H of ABCG8 
would have been required for the study using a two-sided test. To identify which variables in 
childhood predicted the risk of development of gallstones in adulthood, a multivariate stepwise linear 
regression model was performed. The independent variables were gender, BMI in 1980, change in 
BMI between 1980 – 1983, serum values (in 1980) of LDL- and HDL-cholesterol and triglycerides, 
the serum ratios to cholesterol of lathosterol and campesterol, and the ABCG5/8 and NPC1L1 
genotypes. P-value <0.05 was considered significant. The results are expressed as mean ± SEM.   
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3. Results 
 
3.1 Characteristics, food consumption and serum lipids of the subjects evaluated according to D19H 
variant of ABCG8 
The baseline demographics, essential dietary habits and serum lipids of the study subjects (N=192) 
were evaluated in subgroups: gallstone patients (N=66) versus control subjects (N=126), and subjects 
homozygous for the 19D allele in the ABCG8 (N=153) versus subjects with 19H allele (N=39) (Table 
1). 
The mean patient age was 11.8 years at inclusion in 1980 (Table 1). Comparison between the 
subgroups revealed comparable values in demographics (age, sex, weight and height), BMI, and 
serum and lipoprotein lipids (Table 1). The control subjects had reported to consume more frequently 
vegetables than the subjects in the gallstone cohort, but other dietary habits were similar between the 
subgroups in 1980 (Table 1). The mean follow-up time to the diagnosis of gallstone disease was 
22.6±0.8 years. At the time of diagnosis of the gallstone disease, the mean age was 33 years (range, 
31.0 – 37.9 years). 
 
3.2. Cholesterol, ratios to cholesterol of squalene and non-cholesterol sterols in serum of the subjects 
evaluated according to D19H variant of ABCG8 
The gallstone cohort had ~11% lower (p=0.023) campesterol/cholesterol, but ~12% higher (p=0.036) 
lathosterol/campesterol than the controls (Table 2). 
The cohort with 19H allele had 9.7% - 23.4% lower surrogate markers of cholesterol absorption 
(ratios to cholesterol of cholestanol, campesterol, sitosterol, stigmasterol and avenasterol) (p-range 
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<0.001 – 0.009) than the cohort without the variant. Respectively, lathosterol/campesterol was 36.2% 
higher (p=0.008) among the 19H carriers (Table 2). 
 
Relative amounts of subjects carrying the ABCG8 19H allele among the gallstone and control cohorts 
were 22.7% and 19.0%, respectively (p = 0.573) (Table 3). Analysis between the subgroups revealed 
that cholesterol and ratios to cholesterol of squalene, lathosterol, desmosterol and cholestenol in 
serum were comparable (Table 3). The gallstone and the control subgroups with the 19H allele had 
10.2% (p=0.038) and 14.7% (p=0.0006) lower cholestanol/cholesterol than the respective subgroups 
without the 19H allele (=19D homozygotes) (Table 3). 
In the subgroup of gallstone patients with the 19H allele, ratios to cholesterol of campesterol, 
sitosterol and avenasterol were 14.7% - 16.8% lower than in the gallstone subgroup without the 19H 
allele (p-range 0.007-0.055). Parallel to those, the respective values in the 19H carrier controls were 
18.9% - 27.2% lower than in the subgroups without the 19H allele (Table 3). In the gallstone subgroup 
without 19H allele, campesterol/cholesterol, sitosterol/cholesterol and avenasterol/cholesterol were 
11.3% (p=0.062), 11.3% (p=0.034) and 8.7% (p=0.750) lower than respectively in the control 
subgroup without 19H allele (Table 3). The lathosterol/campesterol ratio was 14.1% - 30.4% lower 
in the control subgroup without 19H allele than in the other groups (p-range: 0.008-0.035) (Table 3). 
Subdivision of the study subjects into tertiles (n=64 in each) according to serum 
campesterol/cholesterol (in 1980) revealed that adult gallstone patients belonged mainly to the lowest 
(39%, n=26) and the middle tertiles (39%, n=26) (p=0.024 compared to the highest one, n=14). The 
proportion of the risk allele 19H carriers was higher in the lowest tertile compared to the middle and 
the highest campesterol/cholesterol tertile (p-range 0.001 – 0.020, Figure 1). 
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The frequency of the ABCG8 19H carriers did not differ significantly between subjects with future 
gallstones (non-carriers 77% and carriers 23%) and controls (non-carriers 81% and carriers 19%) 
(p=0.573). 
 
3.3. Cholesterol, ratios to cholesterol of squalene, and non-cholesterol sterols in serum of the subjects 
evaluated according to polymorphism of NPC1L1 locus 
The analysis of the data according to the genetic variants 1679C>G (rs2072183) and -133A>G 
(rs17655652) in NPC1L1 revealed no differences in demographics, in serum cholesterol 
concentrations or in ratios to cholesterol of squalene and non-cholesterol sterols between the 
subgroups (patients and controls with or without variants) (data not shown). Evaluation of the data 
for the variants -18C>A (rs41279633) and V1296V T>C (rs217434) in NPC1L1 showed that solely 
campesterol/cholesterol was ~18% lower in the subgroup of future gallstones and with rs41279633 
C/C and rs217434 T/T genotype than in the other subgroups (p-range 0.012-0.015) (Figure 2). 
Evaluation of the data for the variant g-762T>C (rs2073548) in NPC1L1 revealed ~25% lower 
lathosterol/campesterol –ratio among the mutation carriers of the gallstone group compared to the 
controls having T/T genotype (p=0.009). 
 
3.4. Predictors of gallstone disease 
In the multivariate stepwise linear regression model with the risk of development of gallstones as the 
dependent variable (R2 = 0.060, p=0.01), change in BMI (1980-1983) (β= -0.176, p=0.028) and serum 
campesterol to cholesterol ratio (β= 0.169, p=0.034) were the only statistically significant 
independent predictors of the model. 
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4. Discussion 
The present study represents several new findings. (I) Already in childhood serum non-cholesterol 
sterol surrogate markers of cholesterol absorption were consistently low in the subjects carrying the 
ABCG8 risk allele. (II) These markers were low among the children with future gallstone disease, but 
less consistently than among those having the risk allele. (III) Low relative cholesterol absorption 
was not exclusively limited to the children with future gallstone disease, but was also present in the 
healthy controls carrying the 19H risk allele of ABCG8. (IV) Furthermore, serum 
sitosterol/cholesterol among the children with future gallstones but without the risk allele was ~11% 
lower than respectively in healthy controls without the risk allele. Altogether, these findings suggest 
that (V) low relative cholesterol absorption does not solely explain the risk of future gallstone disease 
in our pediatric gallstone cohort, and the 19H risk allele does not solely explain the low relative 
cholesterol absorption markers among the gallstone cohort. This sounds clinically relevant since there 
are several pathogenic factors having influence on formation of cholesterol gallstones including other 
genetic factors, gallbladder hypomotility, intestinal factors, hepatic hypersecretion of biliary lipids 
and accelerated phase transitions of cholesterol [3, 4]. (VI) The variants of NPC1L1 studied here were 
not related to the gallstone disease. 
Our earlier study showed that the cholesterol metabolism trait characterized by low serum levels of 
non-cholesterol sterol surrogate markers of cholesterol absorption precede the development of adult 
gallstone disease by decades and is present already in childhood [7]. Consequently, low serum 
cholestanol and plant sterol ratios during normal western diet might serve as predictive biomarkers 
for the gallstone disease [7]. These earlier results further support the view that low absorption and 
enhanced biliary secretion of cholesterol and plant sterols are the primary changes in the pathogenesis 
of gallstones [7]. 
The findings of the present study concerning the role of ABCG8 risk variant are parallel to those of 
Krawczyk and co-workers, who showed in their case-control -study that ABCG8 variants did not fully 
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explain the sterol metabolic trait of gallstone disease [5]. Furthermore, the results of the stepwise 
linear regression analysis of the present study indicated that the surrogate of cholesterol absorption 
(campesterol/cholesterol) and the change in BMI, but not D19H of ABCG8 or polymorphisms at 
NPC1L1 locus, predicted the development of gallstones. Results of an earlier study in patients with 
orthotopic liver transplantation indicated that there are alternative pathways for the hepatobiliary 
transport of cholesterol, which are not under regulation of ABCG8 [34]. Further studies are needed to 
evaluate whether ABCG8-independent pathways are essential in regulation biliary secretion of 
cholesterol and plant sterols also in humans, as recently documented in mice [35], and what the role 
of these putative pathways is in the gallstone disease. 
Whether genetic polymorphism of the NPC1L1 sterol transporter affects the risk of the gallstone 
disease has remained controversial. In principle, inhibition of this transporter at the level of the 
hepatocytes (e.g., by loss of function mutations or ezetimibe, an inhibitor of NPC1L1) may lead to 
enhanced biliary cholesterol secretion, thus, facilitating the formation of gallstones. On the other 
hand, increased expression or activity of NPC1L1 transporter at the level of the enterocyte leads to 
enhanced up-take of cholesterol, and, consequently, to elevated levels of cholesterol in serum and 
bile facilitating the gallstone formation. Wang and colleagues observed in their intervention study 
that ezetimibe can significantly reduce cholesterol concentrations and values of cholesterol saturation 
indexes of gallbladder bile in patients with gallstones, mostly attributable to its inhibitory effect on 
intestinal cholesterol absorption [36]. Five common variants of NPC1L1 (i.e., rs17655652, 
rs41279633, rs2072183, rs217434 and rs2073548) have been linked to changes in cholesterol 
metabolism in humans [37-41]. A population based study revealed that genetic variation in NPC1L1 
associated with decreased levels of plasma LDL cholesterol protects against ischaemic heart disease, 
but increases the risk of symptomatic gallstone disease [15]. A controlled Chinese cohort study 
supported the view that the variant rs2072183 of NPC1L1 might be a positive marker for the risk of 
gallstone formation [41]. New findings of the present study were that the above mentioned variants 
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of NPC1L1 have minor influence on serum non-cholesterol sterols in childhood. Furthermore, these 
five variants of NPC1L1 were distributed in equal amounts in the subgroups of the present study. Our 
results suggested that children, who develop gallstone disease in the future and without carriers of 
mutated alleles rs41279633 and rs217434 had low serum campesterol/cholesterol levels, but the 
clinical relevance of this finding remains unclear. 
One of the limitations of this study was that the pigment stones were not identified from gallstones. 
A careful analysis of the composition of gallstone sterols in 165 consecutively cholecystectomized 
adult patients revealed that only 9% of adult gallstones are pigment stones [1]. On this basis, it can 
quite safely be assumed that exclusion of subjects having pigment stones from the present study 
population would not have changed the results of the study. The second limitation is that the possible 
symptoms caused by the gallstones were not recorded. However, this study was focused on resolving 
the etiopathogenesis of incoming gallstone disease in adulthood from the point of view of cholesterol 
metabolism early in childhood, and, thus, it can be considered that the clinical picture of symptoms 
is of secondary importance in this study setting. The third limitation is the relatively low number of 
the study subjects, which prevents sex specific sub-analysis and combination analysis of genetic 
variants in ABCG8 and NPC1L1. The subjects studied here had reached middle-age at the end of the 
follow-up. Some of the study participants, also in the control cohort, may obtain the gallstone disease 
later in life. However, the present study setting allows to reveal the crucial issues in cholesterol 
metabolism in this context. 
We can conclude that the risk allele 19H of ABCG8 is clearly related to low surrogate sterol markers 
of cholesterol absorption already in childhood. Our results confirm the earlier findings [7] indicating 
that individuals, who develop gallstone disease in adulthood are characterized by low serum 
surrogates of cholesterol absorption decades earlier already in childhood. In addition, our new results 
support the view that there are also other factors behind this cholesterol gallstone facilitating trait of 
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cholesterol metabolism than just the risk allele 19H. The variants of NPC1L1 studied here had minor 
influence on serum noncholesterol sterols and cholesterol metabolism. 
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Figure legends 
Figure 1. Distributions of D19H allele genotypes W (=19D allele) and w (=risk allele 19H) of 
ABCG8 in serum campesterol/cholesterol tertiles of the whole study population (n=192). 
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Figure 2. Evaluation of the data according to the variants -18C>A (rs41279633) (A) and V1296V 
T>C (rs217434) (B) of NPC1L1 showed that campesterol/cholesterol ratio in serum was ~18% lower 
in the groups of the gallstone patients homozygous for C (rs41279633) (WW) and homozygous for 
T (rs217434) (WW) than in the other subgroups (p-range 0.012-0.015). Ww/ww: heterozygous or 
homozygous carriers of the allele A of rs41279633 or allele C of rs217434. GS: group of future 
gallstone subjects. 
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Table 1. Demographics, food consumption and lipids and lipoprotein lipids in serum of study 
subjects subdivided into gallstone and control cohorts, and according to variants of D19H of 
ABCG8 gene in year 1980. 
Variables Gallstone Controls   P 19H 19D   P 
    carriers homozygotes  
N n= 66 n= 126  n=39 n= 153  
Age (years) 11.8±0.6 11.4±0.4 0.540 11.2±0.7 11.6±0.4 0.627 
Sex (F/M) 50/16 104/22 0.340 32/7 122/31 0.087 
Weight (kg) 44.6±2.3 42.0±1.6 0.367 42.9±1.5 42.9±2.9 0.962 
Height (cm) 148±3 145±2 0.307 146±2 146±3 0.910 
BMI(kg/m2)   19.2±0.4       19.0±0.3 0.726 19.0±0.6 19.1±0.3 0.883 
BMI(kg/m2)†  20.8±0.5        19.8±0.4 0.104 20.6±0.7 20.0±0.3 0.499 
Vegetables††  2.5±0.1 2.0±0.1 0.002 2.1±0.2 2.1±0.1 0.881 
Fruits and       
juices†† 2.0±0.1 1.9±0.1 0.469 1.8±0.2 1.9±0.1 0.550 
Meat meals†† 2.6±0.1 2.6±0.1 0.925 2.5±0.1 2.6±0.1 0.455 
Fish meals†† 4.4±0.1 4.3±0.1 0.293 4.4±0.1 4.3±0.1 0.848 
Cholesterol 5.2±0.1 5.3±0.1 0.171 5.2±0.1 5.3±0.1 0.401 
LDL-cholesterol 3.3±0.1 3.4±0.1 0.372 3.2±0.1 3.4±0.1 0.101 
HDL-cholesterol 1.6±0.0 1.6±0.0 0.851 1.6±0.0 1.5±0.0 0.146 
Triglycerides 0.7±0.0 0.7±0.0 0.987 0.8±0.1 0.7±0.0 0.334 
 
Values are mean ± SEM. Lipids and lipoprotein lipids are mmol/l. †in year1983, ††Consumption: 1 = 
once a day or more frequently, 2 = almost every day, 3 = twice a week, 4 = once a week, 5 = once 
or twice a month and 6 = seldom or never. 
BMI: body mass index 
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Table 2. Cholesterol and ratios to cholesterol of squalene and noncholesterol sterols in serum of 
study subjects (n=192) subdivided into gallstone and control cohorts, and according to variants of 
D19H of ABCG8 gene in 1980. 
Variables Gallstone Controls P 19H  19D   P 
    carriers homozygotes  
 n= 66 n= 126  n=39 n= 153  
Cholesterol 183.9±3.8 182.8±3.4 0.423 178.6±4.5 184.3±3.0   0.483 
Cholestanol 142.2±3.2 146.8±2.6 0.411 129.5±3.5 149.2±2.3 <0.001 
Cholestenol 9.1±0.4 9.0±0.3 0.264 9.5±0.6 8.9±0.3   0.195 
Desmosterol 74.9±1.4 75.0±1.2 0.818 76.7±2.1 74.5±1.0   0.717 
Lathosterol 88.8±3.7 84.3±3.3 0.162 90.6±5.7 84.6±2.8   0.344 
Campesterol 158.0±8.4 175.0±5.8 0.023 137.2±8.1 177.4±5.4 <0.001 
Sitosterol 105.1±5.5 116.4±4.2 0.717 90.5±5.5 118.1±3.8 <0.001 
Avenasterol 29.2±1.0 32.1±1.0 0.153 26.3±1.4 32.3±0.8 <0.001 
Stigmasterol 17.5±0.6 17.1±0.4 0.733 15.9±0.7 17.6±0.4   0.009 
Squalene 8.3±0.6 8.8±0.5 0.592 7.4±0.4 8.9±0.5   0.184 
Lathosterol/ 0.68±0.05 0.60±0.04 0.036 0.79±0.09 0.58±0.03   0.008 
campesterol       
 
Values are mean ± SEM. Cholesterol: mg/dL. Noncholesterol sterols and squalene: 100x mmol/mol 
of cholesterol 
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Table 3. Serum cholesterol and ratios to cholesterol of squalene and noncholesterol sterols (in 1980) 
of future gallstone patients (n=66) and control subjects (n=126) subdivided according to variants of 
D19H of ABCG8 gene. 
Variables  Gallstone  Gallstone  Controls  Controls   P  
 19D 19H carriers 19D 19H carriers  
 homozygotes  homozygotes   
 n= 51 n=15 n= 102 n= 24  
Cholesterol 185.3±4.2 178.9±8.6 183.8±4.0 178.4±5.2   0.677 
Cholestanol 145.5±3.6a,b 130.7±5.7c 151.0±2.9d 128.8±4.5 <0.001 
Cholestenol 8.9±0.3 9.8±1.0 8.9±0.4 9.4±0.7   0.425 
Desmosterol 74.4±1.5 76.7±3.2 74.6±1.3 76.8±2.8   0.823 
Lathosterol 87.5±3.9 93.1±9.8 83.2±3.8 89.1±7.1   0.407 
Campesterol 163.5±9.9e,f 139.5±13.9g 184.3±6.4h 135.7±10.1 <0.001 
Sitosterol 108.9±6.5i,j 92.3±9.2k 122.8±4.7l 89.4±6.9 <0.001 
Avenasterol 30.4±1.1m,n 25.3±1.9o 33.3±1.1p 27.0±2.0 <0.001 
Stigmasterol 18.0±0.8 15.9±1.0 17.4±0.4 15.8±1.0   0.075 
Squalene 8.7±0.8 7.2±0.6 9.1±0.6 7.5±0.5   0.566 
Lathosterol/        
campesterol 0.64±0.05q 0.79±0.13r 0.55±0.04s 0.79±0.60  0.007 
 
Values are mean ± SEM. Cholesterol: mg/dL. Noncholesterol sterols and squalene: 100x mmol/mol 
of cholesterol. P-value indicates ANOVA comparison between all four groups. 
ap=0.038 compared to Gallstone 19H carriers, bp=0.007 compared to Control 19H carriers, 
cp=0.012 compared to Control 19D homozygotes, dp=0.006 compared to Control 19H carriers. 
ep=0.007 compared to Gallstone 19H carriers, fp= 0.043 compared to Control 19H carriers, gp=0.008 
compared to Control 19D homozygotes, hp=0.0003 compared to Control 19H carriers. 
ip=0.034 compared to Control 19D homozygotes, jp=0.032 compared to Control 19H carriers, 
kp=0.012 compared to Control 19D homozygotes, lp<0.0002 compared to Control 19H carriers. 
mp=0.007 compared to Gallstone 19H carriers, np=0.024 compared to Control 19H carriers, op=0.002 
compared to Control 19D homozygotes, pp=0.003 compared to Control 19H carriers, 
qp=0.021 compared to Control 19D homozygotes, rp=0.035 compared to Control 19D homozygotes, 
sp=0.008 compared to Control 19H carriers. 
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